Bugs, Drugs, and Shrugs

AbstractExperimental evidence “proves” that IL‐17 plays a critical role in the pathogenesis of inflammatory bowel disease, but blocking IL‐17 makes Crohn's disease worse.[1, 2] Only a subset of patients with melanoma benefit from checkpoint inhibitors[3] and only a subset of patients with any rheumatic disease benefit fr om a specific therapy. A scientist at the NIH using a rodent model can't replicate the experimental results of a scientist at Harvard. The intestinal microbiome might provide the explanation for each of these seemingly disparate conundrums.

Source: Arthritis and Rheumatology - November 16, 2019 Category: Rheumatology Authors: James T. Rosenbaum, Lisa Karstens Tags: EDITORIAL Source Type: research